Citi believes Novo Nordisk’s (NVO) announcement this morning that its Wegovy weight loss pill is now broadly available throughout the U.S. will pressure Hims & Hers (HIMS). Hims was again left off Novo’s partners list, which includes CVS Health (CVS) and Costco (COST), LifeMD (LFMD) and GoodRx (GDRX), which likely reflects disagreements between Novo and Hims around Him’s compounded semaglutide strategy, the analyst tells investors in a research note. Citi thinks Novo’s pill launch will put pressure on Hims & Hers’ GLP-1 business in 2026. The firm keeps a Sell rating on the shares with a $30 price target. The stock in premarket trading is up 44c to $33.85.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Mixed options sentiment in Hims and Hers Health with shares down 2.47%
- Mixed options sentiment in Hims and Hers Health with shares down 1.17%
- Hims & Hers Health: Softening Online Metrics and Uncertain GLP-1 Trajectory Drive Underperform (Sell) View
- Insider Sales Shake Up Dell, Hims, Unity, T-Mobile, Southwest
- Sell Rating Issued for Hims & Hers Health Amid Legislative Risks and Overvaluation Concerns